Your browser doesn't support javascript.
loading
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater, Arnon P; Levin, Mark-David; Dubois, Julie; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J; Mous, Rogier; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie F; Dobber, Johan A; Poulsen, Christian B; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C; Ranti, Juha; Brieghel, Christian; Mattsson, Mattias; Bellido, Mar; Tran, Hoa T T; Nasserinejad, Kazem; Niemann, Carsten U.
Afiliación
  • Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: a.p.kater@amsterdamumc.nl.
  • Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.
  • Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Kersting S; Department of Hematology, Haga Hospital, Den Haag, Netherlands.
  • Enggaard L; Department of Hematology, Herlev Hospital, Copenhagen, Denmark.
  • Veldhuis GJ; Department of Hematology, St Antonius Hospital, Sneek, Netherlands.
  • Mous R; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Mellink CHM; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • van der Kevie-Kersemaekers AF; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Dobber JA; Laboratory of Special Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Poulsen CB; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
  • Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Janssens A; Department of Hematology, UZ Leuven, Leuven, Belgium.
  • Schjødt I; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Dompeling EC; Department of Hematology, Isala Ziekenhuis, Zwolle, Netherlands.
  • Ranti J; Department of Hematology, Turku University Central Hospital, Turku, Finland.
  • Brieghel C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Mattsson M; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Tran HTT; Department of Hematology, Akershus University Hospital, Lørenskog, Norway.
  • Nasserinejad K; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.
Lancet Oncol ; 23(6): 818-828, 2022 06.
Article en En | MEDLINE | ID: mdl-35654052
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article